AstraZeneca PLC on Wednesday said Non-Executive Director Bruce Burlington will retire from the board on August 31.
The FTSE 100-listed pharmaceutical said Burlington, who joined the board in 2010, will also step down as a member of the audit committee, the nomination and governance committee and from his role as chairman of the science committee.
Chairman Leif Johansson said: “Bruce has been an exemplary director who has made a significant contribution to the board’s work over many years. We have valued his insightful and frank participation as a board member, and chairman of the science committee during a period of innovation-led transformation at AstraZeneca.
“His diligence and commitment to the work of the audit committee and the nomination and governance committee should also be acknowledged.”
By Maryam Cockar
Source: Alliance News
Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.
Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.